Compare TGE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | SCYX |
|---|---|---|
| Founded | 2023 | 1999 |
| Country | France | United States |
| Employees | 166 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 37.9M |
| IPO Year | N/A | 2014 |
| Metric | TGE | SCYX |
|---|---|---|
| Price | $0.67 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $36.33 |
| AVG Volume (30 Days) | ★ 509.1K | 272.0K |
| Earning Date | 09-30-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $977.86 |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.66 |
| 52 Week High | $3.21 | $6.09 |
| Indicator | TGE | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 34.87 | 36.17 |
| Support Level | N/A | $3.75 |
| Resistance Level | $0.99 | $4.30 |
| Average True Range (ATR) | 0.10 | 0.26 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 3.87 | 14.53 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.